OSR Health Rebrands, Spotlighting $815M VXM01 Licensing Deal and CGM Advances
OSRH•OSR Holdings formally changed its name to OSR Health on June 11, 2026, to align brand identity with its healthcare innovation mission. The company highlights its VXM01 oral cancer immunotherapy licensing deal with Vaximm AG worth up to $815 million in milestones and progress on Woori IO’s non-invasive glucose monitor.
1. Corporate Rebranding to OSR Health
OSR Holdings, Inc. officially amended its corporate name to OSR Health, Inc. effective June 11, 2026, reflecting a clearer focus on its mission to improve health outcomes. The change, filed with the Delaware Secretary of State, does not alter share structure, par value or trading symbol.
2. VXM01 Licensing Milestones
OSR Health emphasized its definitive out-licensing agreement for VXM01, an oral cancer immunotherapy licensed to Vaximm AG. This transaction carries up to $815 million in potential regulatory and sales milestones, representing one of the company’s largest deals to date.
3. Woori IO’s Non-Invasive CGM Progress
The company’s subsidiary Woori IO continues advancing a non-invasive glucose monitoring platform, with strategic engagements including Samsung. Under the FDA’s General Wellness Guidance, this technology could access the US wearable device market sooner than medical-grade alternatives.
4. Value-Creation Framework
OSR Health is evaluating strategic partnerships, subsidiary monetizations, spin-offs and other corporate actions to unlock shareholder value. Management views upcoming inflection points—beyond VXM01—such as Woori IO’s commercialization path, as catalysts for long-term growth.
